Cell and Gene Therapy CMO and CDMO Facilities

Searchable and sortable database of 197 Cell and Gene Therapy CMOs / CDMOs worldwide as of June 2021, including 147 companies and 50 academic or government facilities.

This is a global database of facilities that provide (mostly or exclusively) services as contract manufacturing organizations (CMO) and/or contract development and manufacturing organizations (CDMO) for the cell and gene therapy industry worldwide.

Included: Manufacturers of therapeutic cell products (unmodified or gene-modified), iPS cell lines for therapeutic products, viral vectors and DNA plasmids for cell and gene therapy industry.

Excluded: Contract research organizations (CROs) not performing manufacture of the therapeutic product, vendors of supplies (reagents, devices, etc.) 

For each company:

  • Facility name
  • Link to facility website if available
  • Country of origin
  • CMO/CDMO service expertise
  • Mergers & Acquisitions, Notes
  • The excel file has separate lists for CMO/CDMO that are Industry versus Academic/ Government facilities.

Geographically, our January 2020 database held 69 facilities operating in North America (40%), 69 in Europe (40%), and 35 (20%) in Asia. We had 173 locations for the 161 facilities in our Jan. 2020 database because some of the companies have laboratories in more than one country.

Locations CellTrials.org CMO/CDMO Facilities

Our last release in Sept. 2020 held 188 CMO/CDMO, including 140 companies and 48 academic or government facilities. Since then, we have added 15 organizations (13 industry companies and 2 academic/government) and removed 6 organizations due to acquisitions (Aldevron, Cognate Bioservices, DelphiGenetics, Oxgene, Vigene, Yposkesi). We also recorded the following changes: 7  company name/web-site, 2 country of origin, 3 services, 5 mergers and acquisitions.

Our previous release in March 2020 held 174 CMO/CDMO. Between then and the next release we added 16 organizations (14 industry companies and 2 academic/government) and removed 2 organizations due to acquisitions.

Public samples: